Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Rhea-AI Summary

Anavex Life Sciences (Nasdaq: AVXL) announced its participation in the 7th Annual Evercore ISI HealthCONx Conference 2024 in Coral Gables, FL. CEO Christopher U. Missling will engage in a fireside chat on December 4th, 2024, at 3:25pm ET. The conference brings together over 600 industry experts and leaders from more than 225 healthcare companies, covering sectors including Biotechnology, Pharma, Healthcare Distribution, Services & Technology, Life Science Tools & Diagnostics, and Healthcare Facilities.

The presentation will be available via audio webcast through Anavex's website, with a replay option available later that day. Anavex focuses on developing therapeutics for various conditions including Alzheimer's, Parkinson's, schizophrenia, and Rett syndrome.

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat being held December 4^th, 2024 at 3:25pm ET at the 7th Annual Evercore ISI HealthCONx Conference 2024 in Coral Gables, FL.

This year’s conference features over 600 industry experts and corporate leaders from more than 225 leading healthcare companies. The participating public and private companies will cover all the major healthcare verticals over the entirety of the event, including Biotechnology, Major/Specialty Pharma, Healthcare Distribution, Services & Technology, Life Science Tools & Diagnostics, and Healthcare Facilities & Managed Care.¹

An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX^®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX^®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX^®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX^®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX^®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

---

¹ https://investors.evercore.com/news-releases/news-release-details/evercore-hosts-7th-annual-healthconx-conference-dec-3-5-2024

FAQ

When is Anavex (AVXL) presenting at the Evercore ISI HealthCONx Conference 2024?

Anavex will present on December 4th, 2024, at 3:25pm ET through a fireside chat at the conference in Coral Gables, FL.

How can investors access Anavex's (AVXL) presentation at the HealthCONx Conference?

Investors can access the audio webcast through the Investors section of Anavex's website at www.anavex.com, with a replay available later the same day.

What therapeutic areas does Anavex (AVXL) focus on developing treatments for?

Anavex develops therapeutics for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental disorders, neurodegenerative diseases, and rare diseases including Rett syndrome.

How many companies are participating in the 2024 Evercore ISI HealthCONx Conference where AVXL is presenting?

The conference features more than 225 leading healthcare companies and over 600 industry experts.